Skip to main content
. 2023 Mar 27;2023(3):CD009885. doi: 10.1002/14651858.CD009885.pub3

4.3. Analysis.

4.3

Comparison 4: Additional subgroup analyses of ADHD symptoms, Outcome 3: Parallel‐group trials and first‐period cross‐over trials: comorbidity versus no comorbidity